These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 11592053

  • 1. Peptide/benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors.
    Escherich A, Lutz J, Escrieut C, Fourmy D, van Neuren AS, Müller G, Schafferhans A, Klebe G, Moroder L.
    Biopolymers; ; 56(2):55-76. PubMed ID: 11592053
    [Abstract] [Full Text] [Related]

  • 2. Mapping of ligand binding sites of the cholecystokinin-B/gastrin receptor with lipo-gastrin peptides and molecular modeling.
    Lutz J, Romano-Götsch R, Escrieut C, Fourmy D, Mathä B, Müller G, Kessler H, Moroder L.
    Biopolymers; 1997 Jun; 41(7):799-817. PubMed ID: 9128441
    [Abstract] [Full Text] [Related]

  • 3. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M, Behr TM.
    Biopolymers; 2002 Jun; 66(6):399-418. PubMed ID: 12658727
    [Abstract] [Full Text] [Related]

  • 4. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
    Cappelli A, Anzini M, Vomero S, Menziani MC, De Benedetti PG, Sbacchi M, Clarke GD, Mennuni L.
    J Med Chem; 1996 Feb 16; 39(4):860-72. PubMed ID: 8632410
    [Abstract] [Full Text] [Related]

  • 5. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
    Behr TM, Béhé M, Angerstein C, Gratz S, Mach R, Hagemann L, Jenner N, Stiehler M, Frank-Raue K, Raue F, Becker W.
    Clin Cancer Res; 1999 Oct 16; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
    [Abstract] [Full Text] [Related]

  • 6. CCK-A- and CCK-B-like receptors in the gallbladder and stomach of the alligator (Alligator mississippiensis).
    Oliver AS, Vigna SR.
    Gen Comp Endocrinol; 1997 Jan 16; 105(1):91-101. PubMed ID: 9000471
    [Abstract] [Full Text] [Related]

  • 7. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors.
    Lin CW, Shiosaki K, Miller TR, Witte DG, Bianchi BR, Wolfram CA, Kopecka H, Craig R, Wagenaar F, Nadzan AM.
    Mol Pharmacol; 1991 Mar 16; 39(3):346-51. PubMed ID: 1706470
    [Abstract] [Full Text] [Related]

  • 8. Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.
    Gigoux V, Maigret B, Escrieut C, Silvente-Poirot S, Bouisson M, Fehrentz JA, Moroder L, Gully D, Martinez J, Vaysse N, Fourmy AD.
    Protein Sci; 1999 Nov 16; 8(11):2347-54. PubMed ID: 10595537
    [Abstract] [Full Text] [Related]

  • 9. Insights into the binding and activation sites of the receptors for cholecystokinin and gastrin.
    Foucaud M, Archer-Lahlou E, Marco E, Tikhonova IG, Maigret B, Escrieut C, Langer I, Fourmy D.
    Regul Pept; 2008 Jan 10; 145(1-3):17-23. PubMed ID: 17961734
    [Abstract] [Full Text] [Related]

  • 10. Conformationally constrained CCK8 analogues obtained from a rationally designed peptide library as ligands for cholecystokinin type B receptor.
    De Luca S, Saviano M, Della Moglie R, Digilio G, Bracco C, Aloj L, Tarallo L, Pedone C, Morelli G.
    ChemMedChem; 2006 Sep 10; 1(9):997-1006. PubMed ID: 16915602
    [Abstract] [Full Text] [Related]

  • 11. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
    Boteju LW, Nikiforovich GV, Haskell-Luevano C, Fang SN, Zalewska T, Stropova D, Yamamura HI, Hruby VJ.
    J Med Chem; 1996 Sep 27; 39(20):4120-4. PubMed ID: 8831778
    [Abstract] [Full Text] [Related]

  • 12. Cholecystokinin antagonists: pharmacological and therapeutic potential.
    Herranz R.
    Med Res Rev; 2003 Sep 27; 23(5):559-605. PubMed ID: 12789687
    [Abstract] [Full Text] [Related]

  • 13. Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis cholecystokinin receptor.
    Schmitz F, Pratt DS, Wu MJ, Kolakowski LF, Beinborn M, Kopin AS.
    Mol Pharmacol; 1996 Aug 27; 50(2):436-41. PubMed ID: 8700154
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecystokinin-A receptor antagonists.
    Martín-Martínez M, Bartolomé-Nebreda JM, Gómez-Monterrey I, González-Muñiz R, García-López MT, Ballaz S, Barber A, Fortuño A, Del Río J, Herranz R.
    J Med Chem; 1997 Oct 10; 40(21):3402-7. PubMed ID: 9341915
    [Abstract] [Full Text] [Related]

  • 15. Intermolecular interactions between peptidic and nonpeptidic agonists and the third extracellular loop of the cholecystokinin 1 receptor.
    Giragossian C, Sugg EE, Szewczyk JR, Mierke DF.
    J Med Chem; 2003 Jul 31; 46(16):3476-82. PubMed ID: 12877585
    [Abstract] [Full Text] [Related]

  • 16. Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK(2) antagonists that display high selectivity over CCK(1) receptors.
    McDonald IM, Austin C, Buck IM, Dunstone DJ, Griffin E, Harper EA, Hull RA, Kalindjian SB, Linney ID, Low CM, Pether MJ, Spencer J, Wright PT, Adatia T, Bashall A.
    J Med Chem; 2006 Apr 06; 49(7):2253-61. PubMed ID: 16570921
    [Abstract] [Full Text] [Related]

  • 17. Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists.
    Henke BR, Aquino CJ, Birkemo LS, Croom DK, Dougherty RW, Ervin GN, Grizzle MK, Hirst GC, James MK, Johnson MF, Queen KL, Sherrill RG, Sugg EE, Suh EM, Szewczyk JW, Unwalla RJ, Yingling J, Willson TM.
    J Med Chem; 1997 Aug 15; 40(17):2706-25. PubMed ID: 9276016
    [Abstract] [Full Text] [Related]

  • 18. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling.
    Dong M, Liu G, Pinon DI, Miller LJ.
    Biochemistry; 2005 May 03; 44(17):6693-700. PubMed ID: 15850403
    [Abstract] [Full Text] [Related]

  • 19. Purification, amino acid sequence, synthesis, and receptor selectivity of alligator gastrin.
    Vigna SR, Elsey RM, Cheek AO, Faull KF, Reeve JR.
    Gen Comp Endocrinol; 1997 Nov 03; 108(2):316-26. PubMed ID: 9356227
    [Abstract] [Full Text] [Related]

  • 20. Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist.
    Arlander SJ, Dong M, Ding XQ, Pinon DI, Miller LJ.
    Mol Pharmacol; 2004 Sep 03; 66(3):545-52. PubMed ID: 15322246
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.